Latest Bevacizumab Stories
Introduction of Extended RAS Testing and Recent Clinical Trial Data Will Affect How Physicians Treat Colorectal Cancer Patients, According to Findings from Decision Resources Group BURLINGTON,
DelMar Is Advancing Clinical Trials With VAL-083 As A New Chemotherapy For Refractory Glioblastoma Multiforme VANCOUVER, British Columbia and MENLO PARK, Calif., Aug.
VAL-083 Phase I/II VAL-083 clinical trial advances to 50mg/m(2) cohort VANCOUVER, British Columbia and MENLO PARK, Calif., Aug.
Over Three-Quarters of Physicians View Ophthotech's Fovista as an Emerging Therapy with High Potential Value for Wet AMD, According to Findings from Decision Resources Group BURLINGTON, Mass.,
POINT ROBERTS, Wash. and NEW YORK, Aug.
The Retina Group of New York (RGONY), with offices in Hicksville and Hauppauge, NY, has announced the availability of Ozurdex® (dexamethasone intravitreal implant) as a long-lasting treatment
ResearchMoz presents this most up-to-date research on Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market.
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies.
- totally perplexed and mixed up.